Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Clumeck

Showing results (101-110 of 191) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|July 1, 1983
Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infectionsN Clumeck, B Gordts, I Dab, et al.
Infection|July 1, 1983
Moxalactam therapy of serious infectionsP Van der Auwera, N Clumeck, Y Van Laethem, et al.
HIV Medicine|March 15, 2012
The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baselineJ R Arribas, N Clumeck, M Nelson, et al.
HIV Medicine|August 29, 2013
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trialsJ-M Molina, N Clumeck, C Orkin, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1982
Cefotaxime therapy of serious infections with multiresistant gram-negative bacilliN Clumeck, Y van Laethem, R Vanhoof, et al.
American Journal of Hematology|August 1, 1991
Anticardiolipin antibodies (ACA) are most often not associated with lupus-like anticoagulant (LLAC) in human immunodeficiency virus (HIV) infectionP Capel, A Janssens, N Clumeck, et al.
British Medical Journal|August 14, 1976
Treatment of diabetic coma with small intravenous insulin bolusesN Clumeck, A De Troyer, R Naeije, et al.
Journal of Epidemiology and Community Health|January 8, 2009
Working conditions predict incidence of long-term spells of sick leave due to depression: results from the Belstress I prospective studyN Clumeck, C Kempenaers, I Godin, et al.
Survey of Immunologic Research|January 1, 1985
Thymopentin treatment in AIDS and pre-AIDS patientsN Clumeck, S Cran, P Van de Perre, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1978
Amoxicillin entry into human cerebrospinal fluid: comparison with ampicillinN Clumeck, J P Thys, R Vanhoof, et al.
Pageof 20

Showing results (101-110 of 191) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|July 1, 1983
Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infectionsN Clumeck, B Gordts, I Dab, et al.
Infection|July 1, 1983
Moxalactam therapy of serious infectionsP Van der Auwera, N Clumeck, Y Van Laethem, et al.
HIV Medicine|March 15, 2012
The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baselineJ R Arribas, N Clumeck, M Nelson, et al.
HIV Medicine|August 29, 2013
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trialsJ-M Molina, N Clumeck, C Orkin, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1982
Cefotaxime therapy of serious infections with multiresistant gram-negative bacilliN Clumeck, Y van Laethem, R Vanhoof, et al.
American Journal of Hematology|August 1, 1991
Anticardiolipin antibodies (ACA) are most often not associated with lupus-like anticoagulant (LLAC) in human immunodeficiency virus (HIV) infectionP Capel, A Janssens, N Clumeck, et al.
British Medical Journal|August 14, 1976
Treatment of diabetic coma with small intravenous insulin bolusesN Clumeck, A De Troyer, R Naeije, et al.
Journal of Epidemiology and Community Health|January 8, 2009
Working conditions predict incidence of long-term spells of sick leave due to depression: results from the Belstress I prospective studyN Clumeck, C Kempenaers, I Godin, et al.
Survey of Immunologic Research|January 1, 1985
Thymopentin treatment in AIDS and pre-AIDS patientsN Clumeck, S Cran, P Van de Perre, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1978
Amoxicillin entry into human cerebrospinal fluid: comparison with ampicillinN Clumeck, J P Thys, R Vanhoof, et al.
Pageof 20